APMD vs NVCT: stock comparison and AI forecast
Apnimed, Inc. (APMD) and Nuvectis Pharma, Inc. (NVCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
APMD Apnimed, Inc.
- Price
- $15.06 -47.7% · 6M
- Market Cap
- $627M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVCT Nuvectis Pharma, Inc.
- Market Cap
- $630M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- APMD and NVCT have similar market capitalizations ($627M and $630M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | APMD | NVCT |
|---|---|---|
| Market Cap | $627M | $630M |
| P/B Ratio | – | 69.38x |
| EPS | – | $-1.32 |
| Book Value/Share | – | $0.28 |
Profitability & Margins
| Metric | APMD | NVCT |
|---|---|---|
| ROE | – | -306.6% |
| ROA | – | -124.5% |
Financial Health
| Metric | APMD | NVCT |
|---|---|---|
| Current Ratio | 5.19x | 1.68x |
| D/E Ratio | – | 1.46x |
| Financial Leverage | – | 2.46x |
| Working Capital | $149M | $9M |
Cash Flow
| Metric | APMD | NVCT |
|---|---|---|
| Operating Cash Flow | – | -$20M |
Income Statement
| Metric | APMD | NVCT |
|---|---|---|
| Operating Income | – | -$29M |
| Net Income | – | -$28M |
| R&D Expense | – | $20M |
Dividend & Shareholder Information
| Metric | APMD | NVCT |
|---|---|---|
| Shares Outstanding | 42M | 33M |
APMD vs NVCT: stock comparison and AI forecast
Which is bigger, APMD or NVCT?
APMD and NVCT have similar market capitalizations ($627M and $630M).
Which one does Intratio's AI model rank higher, APMD or NVCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.